OmniAb

OmniAb includes the industry’s only rats for generation of mono- and bispecific human antibodies, OmniRat and OmniFlic.

Ligand's OmniAb platforms - OmniRat, OmniMouse and OmniFlic - are based on novel, transgenic rodents that produce highly diversified antibody repertoires and offer accelerated discovery of fully human antibodies that are naturally optimized in vivo for manufacturability, therapeutic efficacy and reduced immunogenicity - Naturally optimized human antibodies. OmniAb includes the industry’s only rats for generation of mono- and bispecific human antibodies, OmniRat and OmniFlic. OmniMouse provides a complementary murine system for broader epitope coverage. All three platforms have complete freedom-to-operate and allow generation of antibodies specific for all targets and indications globally, unlike some genetically engineered mice on the market. Around 30 biopharmaceutical companies and universities have taken unlimited access to the OmniAb platforms. OmniAb antibodies have been generated against well over 100 targets and several are in clinical development in the US, Europe and Asia just a few years after the platforms where launched.